SBIR/STTR Research Award

Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs

Award identifier 469fb4e0717e3fa77501c7559209337a2f38dbd2558af6aabbb3291751287f3aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,781,519

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ENERGESIS PHARMACEUTICALS INC
Proposal award date
2016-06-20
Contract end date
2020-02-29
UEI
JA9AEU5KN7R1
Solicitation number
PAR14-088
Topic code
200

Research abstract

DESCRIPTION provided by applicant Obesity has reached epidemic proportions in the U S and plays a major role in the development of type diabetes dyslipidemia and cardiovascular disease There remains a very significant need for better non surgical treatments While most weight loss agents rely on suppressing appetite to reduce caloric intake strategies that can safely enhance energy expenditure have the potential to effectively treat obesity Brown adipose tissue BAT is a thermogenic tissue that uniquely expresses mitochondrial UnCoupling Protein UCP This protein dissipates the electrochemical gradient in the mitochondria of brown adipocytes as heat It is increased upon exposure to low temperatures and plays an important role in the maintenance of body temperature and energy balance in rodents BAT is also a flexible tissue that normally enlarges or atrophies over time depending on environmental temperature In many different rodent models enhancement of BAT mass has convincingly been shown to lead to weight loss and diabetes resistance While BAT was until recently thought to be effectively nonexistent in adult humans data obtained in the past several years with PET imaging show that adults in fact have significant BAT and that this tissue is functional Other data demonstrate that the amount of active BAT in individuals is strongly correlated with leanness and that the genetic locus most tightly linked with general obesity causes defective recruitment of new brown adipocytes Until recently no brown adipocyte stem cell had been identified We discovered a population of human skeletal muscle resident brown adipocyte progenitors that under appropriate conditions become fully functional brown adipocytes Following differentiation these cells have high levels of UCP and a very high metabolic rate Using the progenitors we developed an assay for identifying compounds that recruit new mature brown adipocytes We then used this to screen a collection of approved drugs and found several that potently recruit brown adipocytes These hits were validated with dose response testing In the proposed work we aim to further characterize these compounds for potential use as anti obesity therapeutics We will evaluate their suitability for development first in vitro followed by studies in a highly predictive animal model of obesity and insulin resistance If this work is successful we plan to rapidly advance into a proof of concept clinical study with a potential brown fat recruiting product candidate for the treatment of obesity and diabetes PUBLIC HEALTH RELEVANCE Obesity has reached epidemic proportions in the U S and globally While most weight loss agents rely on suppressing appetite to reduce caloric intake increasing energy expenditure is another approach to weight control Brown adipose tissue BAT is a recruitable thermogenic tissue with the capacity to utilize large amounts of fat and glucose and which is present in reduced amounts in obese patients We discovered a human progenitor stem cell for BAT and have used this as a tool to discover approved drugs with the ability to increase the formation of human brown adipocytes Here we propose to further evaluate these compounds in vitro and subsequently in vivo to attempt to identify the compound combinations that most effectively recruit brown adipocytes in a highly predictive animal model of obesity and insulin resistance In doing so we anticipate that this work could identify a potential product candidate that can be rapidly and relatively inexpensively advanced into a proof of concept clinical study with the aim of increasing brown fat and treating obesity i patients

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2011–2021). Reported award amounts total $8,133,350. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.